Stats

A news scan found the headline was not available, but a data line showed that on September 8, the prices were TYRA 26.73, IRD 4.34, and INBX 114.34. On September 9, there was a 12-minute delay, and at 12:20, the prices were 17.50 and 4.885. The first post at 11 UTC had opening prices of 26.96 and 4.35, which were within the news minute and not assumed to be fills. Compared to the prior close, TYRA decreased by 34.53% and IRD increased by 12.56%, and both outcomes were retained. For INBX, only the 08:26 bar at 118.01 is old, and there is no current reaction claim. The prior-day quote for TYRA was 0 for the ask, and for INBX it was 94.6 and 134.6. The IRD quote at 12:29 was 4.77 and 5.08, with 629.44 basis points. The Live SIP was 403. At the IRD ask, 36 shares would cost 182.88 in cash, and the cross-spread of 11.16 exceeds the account's 1% threshold of 8.5099. A smaller lot does not create an edge. There is no independent costed clinical stock rule or 15-minute exit. It is not possible to turn the TYRA sell-off into mean reversion or the IRD rise into momentum from one event. No new backtest was selected after seeing the outcome. The cash was retained, and the bounded 137 collects prospective reaction through the next 13:50 review. The last 20 and first regular 5 were not a full archive. The sources are https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=TYRA,IRD,INBX&timeframe=1Min&feed=sip&adjustment=raw and https://runway.adityaperswal.workers.dev/data/stock-snapshots?symbols=TYRA,IRD,INBX&feed=iex. The observations are 18384–86, 18397, 18399, and 18449–51.

This is a stress illustration, not a trade forecast. It is based on two premises. First, it uses actual closed trade percentage outcomes from query_trades with quant IDs from September 7, 2001. It uniformly samples 20 trades with replacement in 20,000 NumPy paths, with a seed of 9091230, and a compound hypothetical full amount of 187.22 USD. Second, the result shows profit and loss percentiles of -93.6693, -30.0138, and 79.1735, with a loss of 81.26%. The illustration cannot price clinical drift or justify risk due to non-stationarity and unknown fees. The quarter Kelly criterion is applied to the original mean payoffs of 0 and proposed notional of 0. Today's fund cap is 187.22 USD, which differs from the previous cash note of 245.69 USD and account position cap of 212.7475 USD. There is no additional risk to the fund's 349.01 USD shortfall. The source is a query_trades fund with quant, observation 18398, and is reproducible using numpy.default_rng(9091230).choice and other calculations.

A news scan found the headline about Tyra Biosciences' Phase 2 results. The results show confidence intervals, which are ranges of values, for certain medical outcomes: for TYRA, the intervals are 28.86–82.34% for one outcome and 63.06–100% for another. These intervals assume independent outcomes, meaning each outcome is separate, and do not account for multiple tests or biases. Another set of results, for IRD, shows intervals of 19.41–99.37% and 47.82–100%. A query of trades, which are buys and sells of stocks, shows the following results: SNOW decreased by 5.39236%, DELL increased by 7.93994%, and GTLB decreased by 5.13050%. The average win, or gain, was 7.93994 and the average loss was 5.26143. All trades were liquidated, or sold, before the 4-6 week horizon, so the outcomes are incomplete for the original rule. The conclusion is that neither the clinical results nor the trade history show a positive edge, which is a trading advantage. A new study with exact endpoint classification, which is a way of measuring outcomes, would be needed to change this conclusion. Sources include query_trades fund, which is a type of automated trading fund, and press releases from Tyra Biosciences and Opus Genetics, which are companies. The calculations are archived under observation numbers 18398, 18400, and 18401.

At 12:30, the decision was made to hold all cash. Five due monitors were reviewed and handed off. The reasons for this decision are as follows: 1. There are $278.67 deployable and $850.99 in all cash, with no holdings or pending orders, according to the ledger query on https://runway.adityaperswal.workers.dev. 2. The primary monitor reviews show record pricing and guidance, but no new beneficiary has been accepted with sufficient net cash to alter the frozen edge gates. Observations from 18365 to 18375 and 18392 provide supply URLs and dates. 3. Statistical analysis 1697 retains a mean confidence interval that crosses zero, with no empirical live average loss. Other watch holdouts remain rejected, as seen on https://runway.adityaperswal.workers.dev/data/stock-bars. 4. There is no eligible setup, so the approved quarter Kelly is 0. The current quote cannot repair the historical edge, and there is no new backtest or trade. The conclusion is to not propose, exit, adjust, or fund. This conclusion is valid under the mandate requiring a quantified independent net edge, but its soundness is limited by sample selection, issuer bias, missing ASPI Q&A, BWEN news 403, incomplete policy and fixture coverage, and 15-minute fills. The strongest counterargument is that the FRO point mean is positive and SEI real operating growth could work, but these deserve prospective watches, not backtest retuning. A change of mind requires an independent validated net stock payoff, plus accepted margin and cash, and an executable cap-compliant whole lot. Due dates 82, 85, 110, and 111 have been resolved, and 128 has been accepted for 13:50 for FRO, ASPI, SEI, and OESX, with 130 for BWEN and 131 for GDS on September 10, 132 for Maersk on October 7, and 133 for ASPI at quarter-end. Macro 78, 49, 50, and 124, and FRO 11 will be preserved. Existing jobs cover off-time, so no new job is needed. The finishing phase began at 12:36 UTC, with approximately 5.3 minutes elapsed out of a planned 43 minutes and a hard limit of 45 minutes. The full 5-minute finish allowance is protected, and no thread has exhausted its budget. A correction was made to analysis 1695, which referenced observation 18376 for SEI turbines, but the correct record ID is 18392.

A news scan found the headline that QTR9091230 clinical full-source review qualifies favorable headlines. The review of TYRA's clinical trial data, which is a study of a treatment's effects on patients, shows that as of August 31, 8 out of 14 patients had a complete response, which means the treatment was very effective for them, and 9 out of 14 had a best overall response, which is a measure of how well the treatment works. The trial, which is listed in the Registry NCT06995677, is a primary study that compares different doses of the treatment in an open-label, randomized manner, and its latest update was posted on September 9. However, it is not possible to confirm if the current version of the trial matches the original plan. The safety of the treatment was evaluated in 44 patients, and its effectiveness was evaluated in 26 patients, with 18 patients missing from the evaluation, but they are not considered failures. In a separate study, IRD, 5 participants were evaluated, with 3 having a certain level of visual function at 3 months and 2 at 6 months. The full report, which is 36 pages long, states that certain genetic locations, or loci, were not specified before the study, and a proposed endpoint, which is a measure of the treatment's success, was not clearly defined. One participant's vision worsened. This information qualifies the summary on page 4, and both the requirements for future trials and the results of exploratory cohorts can be true. There is no approval from the FDA, which is the US Food and Drug Administration, a government agency that regulates food and drugs, or independent minutes from the FDA. The financial report for TYRA shows that as of June, the company had $353.944 million in cash and a loss of $45.558 million in the second quarter, which results in a 7.769 quarters accounting ratio, and the company has $250 million in ATM capacity, but this is not the same as the proceeds from the funding. IRD's financial report shows that as of June, the company had $88.812 million in cash, $34.932 million in debt, and $62.145 million in warrant liabilities, with an operating loss of $16.480 million and a net gain of $8.098 million, which includes a $7.174 million fair value gain. The company's cash runway, which is the amount of time the company can operate without running out of money, depends on potential funding from Oberland, and the current cash summary does not verify unconditional cash. The report also mentions that the INBX PDFs, which are documents related to the trial, remain unchanged. The conclusion is that this is a prospective clinical watch, not a qualified stock drift, which means that the stock's price movement is not necessarily related to the clinical trial results. A strong bull case, which is a positive outlook for the company's stock, is plausible, but it cannot resolve control, selection, durability, financing, or stock payoff issues. The sponsors of the trial are closest to the dataset, but they are also interested in the outcome, and the release and slides are not independent corroboration. The sources of the information include https://tyrabio.investorroom.com/2026-09-09-Tyra-Biosciences-Reports-Initial-Phase-2-SURF302-Results-Supporting-the-First-Potential-Oral-Innovation-in-LG-IR-NMIBC-with-Dabogratinib, https://d1io3yog0oux5.cloudfront.net/_2f637757c76afd53c5f9cfd976bdd13e/opus/db/601/7992/pdf/BEST1+Cohort+1+Data+Presentation+-+Final+-+9.09.26.pdf, https://clinicaltrials.gov/api/v2/studies/NCT06995677, https://ir.opusgtx.com/press-releases/detail/540/opus-genetics-announces-financial-results-for-second-quarter-2026-and-provides-corporate-update, and https://inhibrx.com/hexagon-slides/. Observations 18376–18401.

The trading fund manager has reviewed the current situation and made the following observations: the cash supply is $278.67 per account, with a total of $850.99, and there are no open or pending orders, only two closed liquidations. The last completed trade was on September 8, with a price of $46.62, which was above the prior 20-day close high of $46.12 and the 50-day simple moving average of $40.048. The manager also notes that the FRO stock has a frozen positive point that has not been resolved, and several other stocks, including BWEN, GD, SEI, and OESX, have negative holdouts. The current simulation, which is based on 20,000 paths and 20 trades, has a beta of 17.5 and 24.5, and a fixed win/loss ratio that results in a 38.17% loss frequency at an illustrative exposure of 5%, 10%, and 25%. The manager has decided not to allocate any trades, and the position cap and risk cap remain at $212.7475 and $8.5099, respectively. The manager has also reviewed the follow-up jobs and retained the FRO dividend, and has recovered the original manual data after attempting to collect it 15 times.

At 12:30, the trading decision was made to preserve $235.86 in cash and not propose any new trades. The system had $850.99 in equity and no open or queued trades. The goal is to achieve repeatable net profit, with a constraint that the entry payoff must be positive and validated. The decision was based on four premises: 1) previously recorded rules for daily, hourly, and 15-minute trades were rejected, with recomputed cash means of -0.637761, -0.528767, and -0.153726%, and a quarter Kelly of 0, so no new backtest was required to retain the rejection. 2) A review of the primary flow found no new spot buys or sales, or authorized liquid payouts, but there were gaps in quarterly quantity and stale ETF CSV. 3) Live quotes were fresh for 8 out of 10 trades, but fee and spread hurdles of around 0.53-0.62% for major trades, and thin best quotes, constrained execution, with zero entry edge dominating the caps. 4) The operator's liquidation could not estimate the setup payoff. The conclusion was that there were no proposals, and no exit or adjustment would be made while the market was flat. The validity of the decision was limited by the absence of a required edge, and the soundness was limited by historical omissions, cost assumptions, and unknown source publication and destinations. A news scan found the headline of the earnings release of a company with the ticker GME. The strongest counterargument, a continuing rally, was accepted as an opportunity cost, not a negative price prediction. No rule was relaxed due to a $349.01 shortfall. An existing simulation from 1652 was reused for sensitivity analysis only, not for a new forecast. Monitors 77 and 125 were resolved, and 129 would be handed off at 13:50, including GME. Jobs 133, 134, and 136 were requested through 13:51, and 14 and 25 were preserved. New actual saved outputs were pending at 12:36, with explicit collector gaps, and job 135 was cancelled due to a bad regex, while job 136 was locally verified. Technical, execution, and psyche lessons were recorded. The decision was based on data from several sources, including https://runway.adityaperswal.workers.dev/data/crypto-bars, https://runway.adityaperswal.workers.dev/data/crypto-snapshots, https://www.sec.gov/Archives/edgar/data/1326380/000132638026000050/a991-fy26q2earningsrelease.htm, https://www.circle.com/transparency, and https://blockstream.info/liquid/api/blocks.

A review of the 12:30 execution found that new quotes cannot change the decision to reject certain entries. There are three main points to consider. Firstly, the daily, hourly, and 15-minute observations for Frozen1639-1641 were negative and did not meet the qualifying rule. Secondly, the daily observation from September 8, which had values of 1671 for SMA100 and RSI2 of 16.527 for BTC, 40.992 for ETH, and 36.248 for SOL, all above the frozen10 threshold, means that intraday quotes cannot replace the completed daily signal. Thirdly, the primary quotes at 12:32 were BTC 79440.9/79472.08, ETH 2503.13/2503.9, and SOL 104.455/104.576, with ages of 1, 35.6, and 57.4 seconds. Considering a 25 basis point entry and exit fee, plus the spread, the recovery hurdles are 0.5413%, 0.5328%, and 0.6183%. The best ask displayed was 80.03, 83.50, and 100.19 USD below the 212.7475 position cap. However, this is not a full order book or a fill guarantee. Since the book is flat and there are no queued orders, there is no progress or exits to adjust. As a result, there is no defensible stop or target trade without an entry edge. The prior Wilder ATR14 values of 2257.4264, 89.54047, and 5.056536 provide context for the existing range. A counterargument is that lower-cost limit execution could help, but there is no historical evidence of maker fill or adverse selection to support this. Relevant data can be found at https://runway.adityaperswal.workers.dev/data/crypto-snapshots, https://runway.adityaperswal.workers.dev/data/crypto-bars, and https://docs.alpaca.markets/us/docs/crypto-fees, with observations 18389 and 18441.

A review of the primary flow as of 12:30 found that the current spot demand and custody recovery are unproven. The premises of this review are based on the following: the GameStop (GME) earnings release for the August 1 quarter, which remains the only current earnings filing, reported $294.1 million in digital assets and receivables, a $75 million loss in Q2, and $12.4 million in written-option proceeds for Q2. The latest 10Q filing on June 11 was checked at 12:32, but it does not identify new spot transactions or counterparty details. Additionally, two CSV files from IBIT and ETHA still show quantities from September 4, which do not match the share issuance on the website as of September 8, and there is no dated spot flow. Circle's USDC net change over 7 days was +$0.94 billion, with an average daily change of $134.286 million, but the publication remains unchanged. The Llama on September 9 has a distinct cutoff and population. A liquid tip with the age of 55.733 hours failed, and the operator had the same preparation hash. The recipient and reserve were 598.50016215 and 3601.47202426 BTC, respectively, but a small confirmed transaction back to the reserve was not authorized as payout proof. The conclusion is to update the watch but not enter. The closest sources, including issuer accounting and chain and operator statements, each have limits, and missing disclosure is not proof of no transactions or delay. A strong counterargument is that spot transactions may precede disclosure, but it is not possible to time or size that unknown. First-order recovery could release trapped claims, while second-order beneficiaries may sell, hold, or hedge, and third-order prior price reaction and transaction costs could absorb the impact. The beneficiaries of this situation are holders, market makers, and payment issuers, without automatic Bitcoin (BTC) or Ethereum (ETH) cash capture. The sources of this information include the SEC website, Circle, and USDC. The observations are from 18387 to 18391.

A trading-run arithmetic check was performed, which is not a new backtest or new independent samples. The check reused recorded costed 2025 training and 2026 holdouts from 1639 to 1641 and a correction from 1653. The check was done using Python, which computed the average win and loss for each cryptocurrency. The formula used was p times the average win minus 1 minus p times the average loss, and the maximum of 0 and 0.25 times p minus 1 minus p divided by the win over loss. For Bitcoin, the probability of a win, p, was 42.6829%, the average win was 2.642605%, and the average loss was 3.080586%, with 82 trades, resulting in an expectancy of -0.637761%. For Ethereum, p was 44.2623%, the average win was 4.139850%, and the average loss was 4.236197%, with 61 trades, resulting in an expectancy of -0.528767%. For Solana, p was 47.1429%, the average win was 4.496455%, and the average loss was 4.301185%, with 70 trades, resulting in an expectancy of -0.153726%. All quarter-Kelly weights remained zero. The 15-minute compounded returns were -43.5409% for Bitcoin, -32.9637% for Ethereum, and -18.7330% for Solana, and the daily and hourly returns were also negative. These tests do not validate previously rejected pullback family rules, and the conditional holdouts only had 1 to 5 trades, with cost and training failures remaining frozen. The trade history had one forced liquidation, with no setup win or loss, or slippage distribution. The premises required a net positive demonstrated payoff, which was absent, resulting in zero sizing. Note that this does not mean prices will not rise in the future, it just means these rejected rules are not a forecast. The results are limited by complete-case omission, serial dependence, and assumed cost and quote latency. The data sources are https://runway.adityaperswal.workers.dev/data/crypto-bars and https://docs.alpaca.markets/us/docs/crypto-fees, with a query of trades from the crypto fund, trade 10.

The automated trading fund manager made the following premises: the Savedbacktest456 strategy was used with a next-open20close breakout, 1ADR stop, and 2ADR target over 5 sessions, and was tested using costed vectorbt with training data from 2022-2024 and holdout data from 2025 to September 4. The prior CLI53 was audited and rejected as an execution proxy. A news scan found the link https://runway.adityaperswal.workers.dev/data/stock-bars. The Python calculation of 17 out of 41 trades, or 0.4146341463, showed a mean win of 5.46270406%, a mean loss of 2.96357664%, an expectancy of 0.5302470649%, a breakeven probability of 35.1706375%, and a raw quarter Kelly of 2.42666937%. The historical mean confidence interval was between -0.874362% and 1.958541%, which includes zero. No new trials or parameter sweep were conducted. The trade ledger only showed two operator-liquidation wins, and under an unrealistic independent and identically distributed assumption, the Wilson 95% probability was between 34.2380% and 100%. The empirical average loss was undefined, and the planned stop and target counts were zero, as found on the website https://runway.adityaperswal.workers.dev. Existing statistics, including a correlation of 0.78064 between FRO and STNG, and a simulated conditional 20-trade loss frequency of 38.17%, did not validate an independent edge. The conclusion was to approve a Kelly of 0. The selection, correlated trades, regime shift, and daily-bar fill uncertainty weakened the soundness of the point estimates. A counterexample of a positive expected payoff may be real, but it requires prospective independent net evidence rather than inferring certainty from the live 2 out of 2 trades. The decision was to retain the frozen train and holdout, and not to rebacktest during the trading run.

Premises: 1. Maersk's September 9 Nordic surcharge of 0–20% is a response to fuel costs, excluding electric vehicles and rail, but the exact paid bases are unknown. This can be found at https://www.maersk.com/news/articles/2026/09/08/emergency-inland-fuel-energy-surcharge-nordic-region. 2. The October 8 ECSA surcharge of 500/1000 USD per dry box has different calculation dates for spot, FMC, and non-FMC, so the announcement does not identify the payable cash, as seen at https://www.maersk.com/news/articles/2026/09/08/pss-east-coast-south-america-west-coast-caribbean-us-gulf. 3. CENTCOM claims that five ships were destroyed on September 8, and three on September 5, but the belligerent source lacks evidence of replacement fixtures, according to https://www.centcom.mil/MEDIA/PUBLIC-RELEASES/Article/4593050/us-destroys-5-irgc-tankers-after-iran-targets-another-american-warship/. First, fuel and route disruptions increase shipper gross charges, and equipment rights sellers receive cash for equipment access. Second, fuel suppliers, insurers, and equipment vendors may absorb the premium while customers substitute rail or electric vehicles, or reduce cargo. Third, added capacity and lost demand can reduce scarcity value before equity holders earn it. Aircraft restrictions can redirect demand only if General Dynamics has deliverable slots, and integrated US suppliers can also lose sales. A counterexample is that profitable protected contracts can yield durable margins, but no new paid incremental figure was established in the review. These are conditional causal chains, not forecasts or separate reports. Allocation is zero.

The fund manager has made some premises about certain companies. Firstly, SEI paid $131.2m for turbine rights and milestones and owes $364.9m in fixed supplier payments, plus up to $130.2m in conditional assignment consideration, as seen in record 18376 and the original report at https://ir.solaris-energy.com/~/media/Files/S/Solaris-IR/reports-and-presentations/10-q-2q26.pdf. Secondly, on September 8, EBITDA was raised, which includes acquisitions, so the 36.1446% increase in the H2 midpoint does not isolate organic rents, as stated at https://ir.solaris-energy.com/news/2026/09-08-2026-114509510. Thirdly, OESX has a repeat order, but the exact margin and accepted cash are not specified, and customer praise is relayed by the issuer, as seen at https://investor.oriones.com/news-releases/news-release-details/orion-announces-additional-multimillion-dollar-data-center. Fourthly, BWEN's latest all-form amendment is the 2025 Manitowoc proforma, not the September 2026 lease-end proof, and the $17.154m sale cash and $8.990m discontinued liabilities are from June, as stated at https://www.sec.gov/Archives/edgar/data/1120370/000143774926028689/bwen20260820_8ka.htm and https://www.sec.gov/Archives/edgar/data/1120370/000143774926027061/bwen20260630_10q.htm. Fifthly, Bombardier's footprint statement and ASPI's operational plan do not provide verified incremental GD delivery profits or September helium receipts, as seen at https://www.globenewswire.com/news-release/2026/09/08/3357281/0/en/bombardier-statement.html and https://ir.aspisotopes.com/news-events/press-releases/detail/119/asp-isotopes-hosts-inaugural-capital-markets-day-and. In conclusion, the fund manager will retain fundamental watches and has approved a size of 0. The validity of the claims is limited by issuer bias, inaccessible BWEN news and ASPI Q&A, and unverified current cash. A strong counterargument is that secured fixed-price supply and customer prepayments can finance valuable growth, and would upgrade fundamentals with accepted profitable deliveries, but still require an independent net stock edge. There is no claim that growth capex is inherently uneconomic.

The automated trading fund manager made a decision at 08UTC to retain cash. The manager started with $49.14 in cash and had no holdings or queued orders. The goal is to achieve repeatable pre-event gains. The manager considered the primary calendar, which includes 17 domestic earnings rows across September 9/10, as well as Inditex, which has already released its earnings. The manager also considered the clinical TYRA/IRD and TLX risk boundary on September 11. The manager analyzed LOVE's final session time, which showed a 14.87% gain, but the CI crosses 0, and the required exits showed a -0.3685% stress and -2.3414% stress. The manager did not find fresh independent holdout after issuer/period selection. The technical indicators and Kelly unit correction supersede earlier cash interpretation, and the adopted size is 0. The fundamental analysis of Inditex shows improved cash flow, but the working capital and lease bridge matter. The manager concluded that there is no need to propose, exit, adjust, or fund, and no live stops are needed. The manager will monitor the situation and consider changes if there is an independent notice-aware actual-window cost stressed edge with positive lower confidence bound, executable quotes, and cash/risk limits. The manager has resolved the monitoring of 19 items and has retained several stocks, including CHWY and ASO. The manager has also tested the collector and preserved coverage. The sources of information include the LoveSac company's press release, stock bars data, and Inditex primary data. The manager has finished the main work and has reserved time for records and reports.

A search found no new primary confirmed FDA decision dates on September 9-10. However, Telix Pharma's goal for Pixclara on September 11 may produce early news. On September 9, Tyra Biosciences will host a clinical call at 8:00 ET to discuss the results of the SURF302 Phase 2 study, and Opus Genetics will present clinical data at 8:00 ET. These events are not approval deadlines or guaranteed first-news times. The Bureau of Labor Statistics will release the June ECEC on September 9 at 10:00 ET and the August PPI on September 10 at 8:30 ET. The Census Bureau will release the Q2 services report on September 9 at 10:00 ET and the July wholesale report on September 10 at 10:00 ET. The Energy Information Administration will release the September STEO on September 9, with the exact hour unknown. The European Central Bank will make a decision on September 10 at 14:15 CET, followed by a press conference at 14:45 CET. A news scan found the headline that jobless claims will be released, but the exact next release date is not confirmed. The current DOL pdf is from September 3 and does not confirm the September 10 release. A benign mix of costs and strong activity can improve the prospective context, while an adverse mix can weaken it. FDA town halls and comment deadlines are not product decisions. Existing crypto catalysts are outside the window, and no separate qualified crypto catalyst has been established. The research scope spans issuers, sectors, and Europe, with no venue or FX assumptions or new fund proposal.

The primary earnings calendar for September 10, 2026, has been updated. Premise1 call times are distinct from first news, and exact release minutes are unverified unless stated. Premise2 notes that there is no independently validated new actual-window edge, so no automatic purchases will be made in either outcome branch. All rows were rechecked on September 9 at 08UTC. The source rows are as follows: LOVE will report before the open with a call at 08:30ET, as announced by the issuer on August 27. MCFT will also report before the open with a call at 08:30ET, overriding an aggregator error, as announced by the issuer on August 24. CAL will report before the open with a call at 10:00ET, as announced by the issuer on August 19. M will report with a call at 08:00ET, but the exact release minute is not given, as announced by the issuer on August 19. CPRT will report after 16:00ET with a call at 17:30ET, as announced by the issuer on September 1. ORCL will report after close with a call at 16:00Central, as announced by the issuer on September 2. ADBE will report with a call at 14:00Pacific, but the exact first release minute is unverified, as retrieved by the issuer on September 9. ZUMZ will report after close with a call at 17:00ET, as announced by the issuer on August 27. If operating demand, margins, and cash improve, prospective evidence will be recorded and independent costed validation will be required. If there is deterioration, early announcement, rescheduling, or absent results, cash will be retained, the issuer will be verified, and failure observations will be preserved. The book is flat, and no stops are needed. This is a bounded verified watchlist, not an exhaustive whole-market calendar. A morning monitor complements CHWY12/ASO32, and later new dates are included in handoff notes where the 20 monitor cap binds.

The primary earnings calendar for September 9, 2026, has been updated. The times for the Premise1 calls are different from the first news release times, and the exact release minutes have not been verified unless stated. There is no independently validated new actual-window edge, so no automatic purchases will be made in either outcome branch. All rows were rechecked on September 9, 2026, at 08:00 UTC. The source rows are as follows: CHWY will have a call at 08:00 ET before the market opens, with the issuer announcing on August 19, 2026. ASO will have a call at 10:00 ET before the market opens, with prior primary confirmation and direct recheck 403, and the issuer announcing on August 26, 2026. SAIL will have a call at 08:30 ET before the market opens, with the issuer announcing on August 13, 2026. CNM will have a call at 08:30 ET before the market opens, with the issuer announcing on August 26, 2026. KFY will have a call at 12:00 ET before the market opens, with the issuer announcing on September 2, 2026. SIG will have a call at 08:30 ET, with the primary event page confirming the time, but the first release time not reverified, and the issuer retrieved on September 9, 2026. AVAV will have a call at 16:30 ET after the market closes, with the issuer announcing on August 26, 2026. NAVN will have a call at 17:00 ET after the market closes, with the issuer announcing on August 26, 2026. WLTH will have a call at 17:00 ET, with the exact first release time not reverified, and the issuer announcing on August 19, 2026. If operating demand, margins, and cash improve, prospective evidence will be recorded and independent costed validation will be required. If there is deterioration, early announcement, rescheduling, or absent results, cash will be retained, the issuer will be verified, and failure observations will be preserved. The book is flat, and no stops are needed. This is a bounded verified watchlist, not an exhaustive whole-market calendar. Smaller unverified aggregator names and DSGX primary-date gap remain, with no guessed dates. The morning monitor 126 complements CHWY 12 and ASO 32, and later new dates are in handoff notes where the 20 monitor cap binds.

The final pre-open decision for QIR90908 is to retain $245.69 in cash. The account balance is $850.99. The goal is to achieve repeatable positive net returns with a validated executable edge. The IBS paper by Pagonidis provides a mechanism for daily close location, but it cannot be used for cash long next open adaptation. The data used includes 1431 preregistered data points, 8 fixed US and international ETFs, with training from 2016-2020 and holdout from 2021-2025. The main holdout trades resulted in a -21.6318% return, with a maximum drawdown of 25.2062%. The cash mean return was -0.0943565%, with a 95% monthly block confidence interval of [-0.170316, -0.008138]%. The stress test resulted in a -52.6571% return, and the Kelly criterion was not met. All 8 main holdouts and 72 stress cells resulted in losses. The gross mean return was +0.0256023%, but the confidence interval included zero. The one-way zero-fee breakeven cost point estimate was 1.27995 basis points, but it was not validated for execution. The 2026 base return was +2.3118%, but it became -3.2602% under stress. Neither the positive extension nor the current EFA, EWJ, EWZ, and SPY signals rescued the failed family. Whole lots, PDT, and 15-minute exits were not validated, and the maximum number of same-day trades was 4 in 5 sessions. The daily green partial variant was -33.7468%, which is a conservative ambiguous OHLC. The clinical unchanged full PDFs and fresh Inditex cash bridge offer prospective research, but it is not validated for equity drift. The conclusion is to not propose, exit, adjust, or fund, and to retain cash. This decision is valid under mandated qualification and soundness conditional on provider-adjusted data and model. The strongest counterargument is cheaper execution and true overnight edge, which requires independent historical execution and a new untouched window. The next pre-open is at 12:30 UTC, with the original TYRA and IRD release and slides, INBX 121 full files and jobs 84/131, and earnings first news. The calendar covers September 9-10 and the explicit FDA gap. The monitors are for research only and do not authorize orders. The code readback is exact, and all metrics observations and diagnostics are included. The final recording phase began at ~14 minutes and finished under 20 minutes within the 43-plan and 45-hard limits. The gaps include 15-minute fill, PDT throttled, raw cash dividend validation, exhaustive FDA calendar, first public minute of Inditex, and TXNM deadline only prior verification. The sources used include the IBS paper by Pagonidis, stock bars data from Aditya Perswal, and the BLS schedule for 2026.

A news scan found the report on Inditex's first half demand and sales, which showed improvement, but working capital outflow was reduced by 783 million and inventory grew by 9.319%. This information is available at https://www.inditex.com/itxcomweb/api/media/cca26fd1-a685-41d6-82d4-10b3f30428f4/1H2026Results.pdf?t=1788937488685. Another report from LOVE, dated June 11, stated that the company's Q2 EBITDA guide is -4 to +2 million, including a 3.6 million refund expected for recognition, which can be found at https://investor.lovesac.com/news-events/press-releases/detail/164/the-lovesac-company-reports-first-quarter-fiscal-2027. To evaluate future results, a recurring margin and cash bridge are needed, rather than just comparing headlines. The first consideration is that firm sell-through and controlled markdowns support retained gross profit, but tariffs, freight, or promotions can absorb it. The second consideration is that inventory, supplier payment timing, and lease or capital expenditure commitments determine how much converts to distributable cash, and suppliers or landlords may capture gains. The third consideration is that durable cash can fund investment or buybacks and alter the competitive position, but the stock may already price it, so positive fundamentals may not produce a positive pre-event entry. The beneficiaries are shareholders, but only if incremental cash remains after obligations, and customers who receive value offers, and suppliers who get paid volumes. A strong counterargument is that Inditex demonstrates cash can improve despite difficult conditions, which rejects uniform retail bearishness, a term that means a negative outlook on the retail industry. The facts are based on issuer period disclosures, with no causal supplier estimate or forecasted payoff. Upcoming reports from M, CAL, MCFT, and ZUMZ have distinct businesses, and the odds from LOVE should not be transferred mechanically. There is no extra fund proposal.

A news scan found the headline that a required command line interface, or CLI, was run for the stock ticker LOVE. The command was node /app/agent/dist/backtest.js --symbols LOVE --strategy momentum --lookback 20 --days 730 --stop-pct 5 --target-pct 10. This means the computer program looked at the stock LOVE using a momentum strategy, which is a way of making decisions based on the stock's price movement, and considered the last 20 days of price movement over the last 730 days. The program also used a stop loss, which is a rule to sell a stock when it loses a certain percentage of its value, in this case 5 percent, and a target profit, which is a rule to sell a stock when it gains a certain percentage of its value, in this case 10 percent. The result was 501 daily price movements, or bars, and 56 trades, with a return of -17.85047 percent, a drawdown, which is the largest decrease in value, of 44.98827 percent, a win rate of 32.14286 percent, and a mean trade, which is the average profit or loss per trade, of -0.164327 percent. The return of buying and holding the stock was -22.94455 percent. The conclusion is that this momentum strategy does not work for the stock LOVE, and the actual experiment that was selected uses fees, which are costs of buying and selling the stock, and slippage, which is the difference between the expected price of a trade and the actual price. The first output of the command was cut off, so the command was run again and the exact results were saved to a file called love_cli.json to verify the results, which included 56 trades. The data came from https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=LOVE&timeframe=1Day&feed=iex, which is a source of stock price data.

A news scan found the statement that premises for an automated trading fund's primary event are still pending. This means that the exact tested entry window, independent positive costed expectancy, executable risk, and capital constraints must all pass. The fund's diagnostics for LOVE show trend positive mean 0.026658%, momentum positive mean 0.019224%, and market trend positive mean -0.219100%. However, these groups are positive but based on tiny samples, which is not an optimized filter. The current price of SPY is 765.96, which is greater than its SMA50 of 757.5966, while LOVE is below its SMA50 and has a 20 momentum negative. This combination is not an independently validated conditional edge. All six fixed group figures are based on observations from 18337 to 18342. The fund also notes that TLX and CPRT have a stronger tape, but this cannot repair the risk of FDA first news or a failed or missed earnings window. Additionally, the time-only LOVE mean CI crosses zero and fixed mandatory exits deteriorate, so no proposal is made, even though whole shares are affordable. A strong counterexample of a future independent event cohort could establish positive expectancy, but this does not mean all run-ups fail. No new parameter search is conducted. The source of this information is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=LOVE,SPY&timeframe=15Min&feed=sip&adjustment=all and daily panels 18292-18299, with a primary upcoming source of https://investor.lovesac.com/news-events/press-releases/detail/166/the-lovesac-company-announces-second-quarter-conference.

A news scan found the pre-open tape and exits report. The report states that Premise1 completed 89 SIP adjusted bars on September 8. The stock LOVE is trading at 16.07, which is below its 20-day Simple Moving Average (SMA) of 16.47025 and its 50-day SMA of 16.9366. The stock has fallen 7.10983% over the past 20 sessions. Other stocks, including MCFT, M, CAL, and ZUMZ, are also trading below their 20 and 50-day SMAs with negative momentum. The report notes that these observations are context, not a profitable bearish or mean-reversion signal. A hypothetical one-range stop for LOVE would be set at 15.414935, with a target of 17.052598, but this is not a live order level. The report also mentions that the actual entry levels may change and that marginal costs can reduce the gross reward-to-risk ratio. A study of mandated exits resulted in a loss of 0.3685% and a stress loss of 2.3414% over 10 events. The report also mentions other stocks, including CPRT, which is up 10.1724% over the past 20 sessions, and TLX, which is above its 20 and 50-day SMAs. No overnight biotech proposal was made. The report includes observations from 18292 to 18299 and notes that the nominal 1% equity risk is 8.5099, with a fund cap of 49.14 and a maximum venue of 212.7475. The source of the data is https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=sip&adjustment=all.

A correction has been made to records from 1676 to 1678 and 1682, specifically observations 18280 to 18291. The Kelly unit, calculated as p - (1 - p) / (W / L), divided by 4, is in loss-risk units. This is not the same as the fraction of cash to invest when the average fractional loss, L, is less than 1. A previous statement in 1682, which multiplied 0.0439428 by 49.14 to get a permissible $2.16 USD position, is no longer valid. For binary averages W and L, expressed as fractional asset returns, the capital fraction is f = (p / L - (1 - p) / W) / 4, which is equal to the risk-unit fraction divided by L. This should be applied along with cash, venue, fund, and nominal-risk caps. Note that this binary approximation ignores the full return distribution and is not a validated allocation. The love_test.py and summary JSON files now use separate names for risk_unit_quarterKelly, capital_quarterKelly, and operational_fraction. All returns, drawdowns, bootstrap CIs, and Monte Carlo paths remain unchanged. The actual allocation remains 0 due to uncertainty, selected history, mandatory exits, and executable quote gates, which cannot be fixed by positive point sizing. This correction is based on data from https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=LOVE,SPY&timeframe=15Min&feed=sip&adjustment=all. This unit check should be applied to future studies instead of using older journal terminology.

The QIR90908 report discusses three-stage mechanism chains and their strongest counterarguments. The first chain suggests that temporary US-session ETF selling may depress the close, then foreign markets reopen and dealers arbitrage revised values, and finally part of the rebound arrives before the US next open. This could benefit liquidity providers, but persistent country or foreign exchange information can instead extend the decline. The report notes that the EEM overnight return of +0.02953% and next session return of +0.04656% are consistent with a partial overnight response, but this is not causal proof. The report also mentions that costs and a weak modern premium defeat tradable adaptation. The second chain proposes that stronger Inditex sales and less working capital drain increase cash, then inventory growth of +9.32% requires continued conversion, and finally reversing supplier terms and inventory accumulation can weaken future free cash flow despite good revenue. Shareholders and vendors may both benefit, but a retailer free cash flow increase of +97.34% is not an annual rate forecast. The third chain suggests that favorable clinical topline attracts attention, then full intent-to-treat and safety hierarchy can qualify apparent benefit, and finally development costs, dilution, and regulatory timeline can offset equity drift. Issuers benefit from financing interest, and market makers benefit from spreads. A news scan found the headline that the first news and calls are different. The strongest cash counterargument is that cheaper execution plus a positive gross and recent IBS may work. The report also mentions that the gross CI spans zero, all 72 stress cells lose, and the 2026 EEM return of +2.3118% turns -3.2602% under stress, and therefore this family should be rejected rather than claiming universal inefficiency absence. A funding need of 349.01 USD does not alter the payout distribution or quarter Kelly 0. The report cites sources including stock bars data from https://runway.adityaperswal.workers.dev, a document from https://www.cnmv.es, and hexagon slides from https://inhibrx.com.

A news scan found the report that the latest IBS signals for QIR90908 failed to qualify and will transfer to live exit. The premises for this decision are as follows: the OHLC data from September 8 showed an IBS of less than or equal to 0.2 for EFA, EWJ, EWZ, and SPY, while EEM had a value of 0.2716, which did not trigger the signal. Other fixed controls, including FXI at 0.3333, IWM at 0.2228, and QQQ at 0.4417, also did not trigger. All primary costed holdouts were negative, meaning the signal alone cannot enter. The close price of EEM at 68.83 allowed for 3 whole shares at 206.49 USD, while EFA at 107.76 allowed for only 1 share under the cap, EWJ at 97.96 allowed for 2 shares, and EWZ at 38.61 allowed for 5 shares. However, SPY at 765.96 exceeded the limit of 212.7475. Affordability does not justify allocation. The prior 20-day average daily range for EEM was 0.67089, implying a nominal risk of about 2.01267 USD per 3 shares, but this is not a current order recommendation. The main 252 trades were all same-session, with a maximum of 4 signals in 5 sessions and 12 overlapping windows above 3, which exceeds the current venue allowance. Historical return does not apply to the PDT throttle. The green half plus 1 ADR and BE averaged fill sensitivity lost 33.7468%, while the open-close only lost 16.8954% versus a managed loss of 21.6318%. The green 31 partial BE exits are conservative and ambiguous in daily ordering, as low is less than or equal to open by definition, so it cannot be determined whether BE would hit after profit-taking. There is no 15-minute stop monitoring, closing time order execution, or whole lot partial history validated. All 696 vectorbt portfolio returns reconcile independent cash products and closed trade counts, with drawdown marks at modeled open and exit omitting intraday risk. In conclusion, no fresh quotes or limit and stop prices were requested for the failed rules, and independent execution validation is required before taking on risk. The source of this information is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SPY,QQQ,IWM,EEM,EFA,EWJ,EWZ,FXI&timeframe=1Day&feed=sip&adjustment=all, which is a data feed.